Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced o...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022524/ https://www.ncbi.nlm.nih.gov/pubmed/29623575 http://dx.doi.org/10.1007/s10549-018-4778-y |
_version_ | 1783335696596992000 |
---|---|
author | Rau, Kun-Ming Ou-Yang, Fu Chao, Ta-Chung Kuo, Yao-Lung Cheng, Tsui-Fen Chao, Tsu-Yi Chen, Dar-Ren Tzeng, Yen-Dun Wang, Being-Whey Liu, Chun-Yu Hu, Ming-Hung Lu, Yin-Che Ou, Wei-Jen Kuo, Chin-Ho Chuang, Chieh-Han Kan, Jung-Yu Chen, Fang-Ming Hou, Ming-Feng |
author_facet | Rau, Kun-Ming Ou-Yang, Fu Chao, Ta-Chung Kuo, Yao-Lung Cheng, Tsui-Fen Chao, Tsu-Yi Chen, Dar-Ren Tzeng, Yen-Dun Wang, Being-Whey Liu, Chun-Yu Hu, Ming-Hung Lu, Yin-Che Ou, Wei-Jen Kuo, Chin-Ho Chuang, Chieh-Han Kan, Jung-Yu Chen, Fang-Ming Hou, Ming-Feng |
author_sort | Rau, Kun-Ming |
collection | PubMed |
description | PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. CONCLUSIONS: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women. |
format | Online Article Text |
id | pubmed-6022524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-60225242018-07-06 Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan Rau, Kun-Ming Ou-Yang, Fu Chao, Ta-Chung Kuo, Yao-Lung Cheng, Tsui-Fen Chao, Tsu-Yi Chen, Dar-Ren Tzeng, Yen-Dun Wang, Being-Whey Liu, Chun-Yu Hu, Ming-Hung Lu, Yin-Che Ou, Wei-Jen Kuo, Chin-Ho Chuang, Chieh-Han Kan, Jung-Yu Chen, Fang-Ming Hou, Ming-Feng Breast Cancer Res Treat Epidemiology PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. CONCLUSIONS: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women. Springer US 2018-04-05 2018 /pmc/articles/PMC6022524/ /pubmed/29623575 http://dx.doi.org/10.1007/s10549-018-4778-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Epidemiology Rau, Kun-Ming Ou-Yang, Fu Chao, Ta-Chung Kuo, Yao-Lung Cheng, Tsui-Fen Chao, Tsu-Yi Chen, Dar-Ren Tzeng, Yen-Dun Wang, Being-Whey Liu, Chun-Yu Hu, Ming-Hung Lu, Yin-Che Ou, Wei-Jen Kuo, Chin-Ho Chuang, Chieh-Han Kan, Jung-Yu Chen, Fang-Ming Hou, Ming-Feng Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title_full | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title_fullStr | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title_full_unstemmed | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title_short | Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan |
title_sort | effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in taiwan |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022524/ https://www.ncbi.nlm.nih.gov/pubmed/29623575 http://dx.doi.org/10.1007/s10549-018-4778-y |
work_keys_str_mv | AT raukunming effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT ouyangfu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chaotachung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT kuoyaolung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chengtsuifen effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chaotsuyi effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chendarren effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT tzengyendun effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT wangbeingwhey effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT liuchunyu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT huminghung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT luyinche effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT ouweijen effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT kuochinho effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chuangchiehhan effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT kanjungyu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT chenfangming effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan AT houmingfeng effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan |